FDA warns Lifescan recall letter is misleading
This article was originally published in Clinica
The US FDA says it is concerned that the product replacement programme, which the Johnson & Johnson subsidiary, Lifescan, implemented in June for its SureStep blood glucose meters, may cause both consumers and distributors to underestimate the seriousness of the recall.
You may also be interested in...
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.